Dupuytrens disease (DD) is a medical condition characterized by abnormal growth of cells and fibers in the hand which results in formation of rope-like lumps known as nodules under the skin of the hand. The thickening cords cause fingers to bend towards the palm of the hand which makes the straightening of fingers difficult and causes pain and stiffness. The DD treatment market involves pharmaceutical therapy, surgery, minimally invasive surgeries and other alternative therapies. The pharmaceutical therapy includes anti-collagenase ointments and drugs like collagenase clostridium histolyticum that clears cords and lumps. The surgical treatment involves either partial or full removal of collagens cords and lumps.
The Global Dupuytrens Disease Market is estimated to be valued at Us$ 4.3 Bn in 2024 and is expected to exhibit a CAGR Of 4.6% over the forecast period 2024 To 2030.
Key players operating in the Global Dupuytrens Disease Market Demand are Endo International Plc, Bristol-Meyers Squibb Company, Spear Pharmaceuticals, GSK Plc., AstraZeneca, Hikma Pharmaceuticals Plc, LEO Pharma A/S, Fresenius Kabi AG, Bayer AG, Novartis AG, Pfizer Inc., Nantong Jinghua Pharmaceutical Co., Ltd., and Actiza Pharmaceutical Pvt. Ltd., 180 Life Sciences Corp. Growing number of diagnostic centers coupled with increasing adoption of minimally invasive surgeries for DD treatment is fuelling the market growth. Technological advancements in cord lysis drugs, surgical devices and laser therapy devices are further propelling the Dupuytrens disease treatment market.
There is a rising trend of combination drug therapies involving anti-collagenase ointments and cord lysis drugs to improve treatment outcomes. The adoption of advanced imaging techniques like MRI, ultrasound is helping in accurate diagnosis and treatment planning.
Emerging economies in Asia Pacific and Latin America present significant opportunities for global players owing to growing healthcare investments, increasing awareness about DD treatment and expanding healthcare infrastructures. Innovation of non-surgical treatment approaches involving lasers, shockwaves, splinting, radiotherapy etc. opens up new avenues for market players.
Impact of COVID-19 on the Global Dupuytrens Disease Market
The COVID-19 pandemic has adversely impacted the global Dupuytren's disease market. With the imposition of nationwide lockdowns globally in 2020 and 2021, hospitals and clinics focused more on treating COVID-19 patients resulting in cancellation or postponement of non-essential procedures like Dupuytren's contracture surgery. This disrupted the flow of new patient registrations, negatively affecting market revenues. However, with economic activities restarting and healthcare systems adapting to the 'new normal', the number of surgeries performed has gradually increased from mid-2021.
The pre-COVID market was growing steadily at a CAGR of 4.6% driven by rising geriatric population, increasing prevalence of associated risk factors like diabetes, and enhanced clinical awareness. Post-COVID, growth is expected to regain lost momentum especially in 2022 and beyond as backlogs are cleared. However, short-term risks from potential future outbreaks cannot be ruled out. Pharmaceutical companies are focusing on pipeline development and new product launches to sustain long-term growth. For instance, affordable biologics and less invasive procedures can boost accessibility in lower resource settings most impacted due to pandemic-related healthcare budget cuts.
North America accounts for the largest share in the global Dupuytren's disease market in terms of value. This is attributed to high diagnosis and treatment rates supported by favorable reimbursement policies and consolidating pharmaceutical industry presence in the region. Asia Pacific is projected to be the fastest growing market during the forecast period owing to rising healthcare expenditure, speedy economic growth and increasing geriatric population in major countries like India and China. Latin America and Middle East & Africa also offer promising opportunities for market players to expand in the long run.
Europe holds a significant share of the global Dupuytren's disease market and is anticipated to maintain its strong position through 2030. Countries like Germany, UK and France have advanced healthcare systems enabling higher accessibility for Dupuytren's contracture treatment modalities including surgery, needle fasciotomy and collagenase injections. Presence of major market players also aids regional market growth. Though short-term economic challenges exist currently due to COVID-19 induced macroeconomic slowdown, long-term growth drivers remain stable.
Get more insights on this topic :